Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 189.93

+0.5%

Jan 2 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (24458)	8/13/1998 2:49:00 PM
From: Henry Niman	of 32384

Bob, The acquisition is supposed to be accretive next year. Although the target population is small, the profits may be somewhat larger than expected because LGND plans on charging about $40,000 for a treatment course. In addition, they will soon be starting a non-Hodgkin's lymphoma trial, so it wouldn't take much off label market penetration to produce some significant earnings. LGND of course will also use the drug to get its sale force in gear. Sometime next year they should have three CTCL treatments (injected ONTAK as well as topical and oral Targretin) to sell, in addition to a topical KS drug (Panretin). Of course their biggest profits will come from sale of drugs developed in house, and the sooner the sales force gets rolling, the sooner LGND will see profits.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next